Intriguingly, in a mouse model of prostate cancer, the combination of a uropathic strain of E. coli (administered intraurethrally) with systemic anti-PD-1 therapy resulted in improved T-cell infiltration, prostate cancer regression and survival (39). The gene discussed is PDCD1; the disease is prostate cancer.